Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in parkinsonian rats

Journal of Molecular Neuroscience

Volumn 48, Issue 3, 2012, Pages 565-573

  Korkmaz, Orhan Tansel ^a,b,c   Ay, Hakan ^a   Ulupinar, Emel ^a   Tunçel, Neşe ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 OHDA; Medium spiny neurons; Optical fractionator; Striatum; TH immunohistochemistry; Vasoactive intestinal peptide

Indexed keywords

OXIDOPAMINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL STRUCTURE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MOTOR DYSFUNCTION; MYELIN SHEATH; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; RAT; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; ANTIPARKINSON AGENTS; CELL COUNT; CORPUS STRIATUM; DENDRITES; DOPAMINERGIC NEURONS; DRUG EVALUATION, PRECLINICAL; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; STAINING AND LABELING; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA; PARKINSONIA; RATTUS;

EID: 84868210848     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-012-9781-x     Document Type: Article

References (61)

1. Baquet ZC, Williams D, Brody J, Smeyne RJ (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161(4):1082-1090
2. Bezard E, Gross CE, Brotchie JM (2003) Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26(4):215-221 (Pubitemid 36412004)
3. Brenneman DE (1988) Regulation of activity-linked neuronal survival by vasoactive intestinal peptide. Ann NY Acad Sci 527:595-597
4. Brenneman DE, Gozes I (1996) A femtomolar-acting neuroprotective peptide. J Clin Invest 97(10):2299-2307 (Pubitemid 26165719)
5. Brown DR (2000) Neuronal release of vasoactive intestinal peptide is important to astrocytic protection of neurons from glutamate toxicity. Mol Cell Neurosci 15:465-475 (Pubitemid 30395371)
6. Casetta I, Govoni V, Granieri E (2005) Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Design 11 (16):2033-2052 (Pubitemid 40766840)
7. Day M, Wang Z, Ding J et al (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9(2):251-259 (Pubitemid 43164549)
8. Dejda A, Sokołowska P, Nowak JZ (2005) Neuroprotective potential of three neuropeptides PACAP VIP and PHI. Pharmacol Rep 57 (3):307-320 (Pubitemid 41030690)
9. Delgado M, Ganea D (2003a) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17(3):944-953
10. Delgado M, Ganea D (2003b) Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J 17:88-104
11. Delgado M, Abad C, Martinez C et al (2002) Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune disease. J Mol Med 80:16-24 (Pubitemid 34143404)
12. Deutch AY, Colbran RJ, Winder DJ (2007) Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 13(3):251-258
13. Dogrukol-Ak D, Banks WA, Tuncel N, Tuncel M (2003) Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides 24:437-444 (Pubitemid 36561216)
14. Durieux PF, Schiffmann SN, de Kerchoved'Exaerde A (2011) Targeting neuronal populations of the striatum. Front Neuroanat 5:40
15. Feyder M, Bonito-Oliva A, Fisone G (2011) L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosc 5:71
16. Garcia BG, Neely MD, Deutch AY (2010) Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Cereb Cortex 20(10):2423-2432
17. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M (2001) Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 7:89-111 (Pubitemid 32409709)
18. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Varela N, Delgado M (2005) Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 9:923-929 (Pubitemid 41488830)
19. Gressens P (1999) VIP neuroprotection against excitotoxic lesions of the developing mouse brain. Ann NY Acad Sci 897:109-124 (Pubitemid 30040324)
20. Hill JM,Mervis RF, Politi J et al (1994) Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann NYAcad Sci 31(739):211-225
21. Hill JM, Hauser JM, Sheppard LM et al (2007) Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci 31 (3):183-200 (Pubitemid 47338413)
22. Incerti M, Vink J, Roberson R, Benassou I, Abebe D, Spong CY (2010) Prevention of the alcohol-induced changes in brainderived neurotrophic factor expression using neuroprotective peptides in a model of fetal alcohol syndrome. Am J Obstet Gynecol 202(5):457 e1-4
23. Ingham CA, Hood SH, Arbuthnott GW (1989) Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res 4 503(2):334-338 (Pubitemid 19285531)
24. Jan YN, Jan LY (2003) The control of dendrite development. Neuron 40(2):229-242 (Pubitemid 37244094)
25. Joo KM, Chung YH, Kim MK et al (2004) Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol 476(4):388-413 (Pubitemid 39025246)
26. KorkmazOT, Tuncel N, OncuEMet al (2010)Vasoactive intestinal peptide (VIP) treatment of parkinsonian rats increases thalamic gammaaminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci 41(2):278-287
27. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P (1996) Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Ann NY AcadSci 26 805:94-109, discussion 110-111
28. Lerner TN, Kreitzer AC (2011) Neuromodulatory control of striatal plasticity and behavior. Curr Opin Neurobiol 21(2):322-327
29. Liévens JC, Salin P, Had-Aissouni L, Mahy N, Kerkerian-Le GL (2000) Differential effects of corticostriatal and thalamostriatal deafferentation on expression of the glutamate transporter GLT1 in the rat striatum. J Neurochem 74(3):909-919 (Pubitemid 30104286)
30. Magarinos AM, Li CJ, Gal TJ et al (2011) Effect of brain-derived neurotrophic factor haploinsufficiency on stress-induced remodeling of hippocampal neurons. Hippocampus 21(3):253-264
31. Murphy DD, Segal M (1997) Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci USA 18 94(4):1482-1487 (Pubitemid 27087877)
32. Neely MD, Schmidt DE, Deutch AY (2007) Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons. Neuroscience 149(2):457-464 (Pubitemid 47576538)
33. Nishijima I, Yamagata T, Spencer CM et al (2006) Secretin receptordeficient mice exhibit impaired synaptic plasticity and social behavior. Hum Mol Genet 15(21):3241-3250 (Pubitemid 44605503)
34. Nishimoto M, Miyakawa H, Wada K, Furuta A (2011) Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters. Brain Res 6 (1383):43-53
35. Offen D, Sherki Y, Melamed E et al (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854(1-2):257-262 (Pubitemid 30067687)
36. Oorschot DE (1996) Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J Comp Neurol 366:580-599 (Pubitemid 26087296)
37. Passemard S, Sokolowska P, Schwendimann L, Gressens P (2011) VIP-induced neuroprotection of the developing brain. Curr Pharm Des 17(10):1036-1039
38. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates, 3rd edn. Academic, New York
39. Pellegri G, Magistretti PJ, Martin JL (1998) VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur J Neurosci 10(1):272-280 (Pubitemid 28325449)
40. Penrod RD, Kourrich S, Kearney E, Thomas MJ, Lanier LM (2011) An embryonic culture system for the investigation of striatal medium spiny neuron dendritic spine development and plasticity. J Neurosci Meth 30(200):1-13
41. Rangon CM, Dicou E, Goursaud S et al (2006) Mechanisms of VIPinduced neuroprotection against neonatal excitotoxicity. Ann NY Acad Sci 1070:512-517 (Pubitemid 44126695)
42. Reglodi D, Tamás A, Lubics A, Szalontay L, Lengvári I (2004) Morphological and functional effects of PACAP in 6- hydroxydopamine- induced lesion of the substantia nigra in rats. Regul Pept 123(1-3):85-94 (Pubitemid 39424153)
43. Said SI, Dickman KG (2000) Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Regul Pept 93:21-29
44. Said SI, Berisha HI, Pakbaz H (1995) N-methyl-D-aspartate receptors outside the central nervous system: activation causes acute lung injury that is mediated by nitric oxide synthesis and prevented by vasoactive intestinal peptide. Neuroscience 65:943-946
45. Sholl DA (1953) Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87(4):387-406
46. Smith Y, Villalba RM, Raju DV (2009) Striatal spine plasticity in Parkinson's disease: pathological or not? Parkinsonism Relat Disord 15(Suppl 3):156-161
47. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata- Salaman CR (2005) Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 25(3):225-238
48. Solis O, Limón DI, Flores-Hernández J, Flores G (2007) Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease. Synapse 61(6):450-458 (Pubitemid 46559542)
49. Stephens B, Mueller AJ, Shering AF et al (2005) Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 132(3):741-754
50. Stranahan AM (2011) Physiological variability in brain-derived neurotrophic factor expression predicts dendritic spine density in the mouse dentate gyrus. Neurosci Lett 495(1):60-62
51. Theriault E, Landis DM (1987) Morphology of striatal neurons containing VIP-like immunoreactivity. J Comp Neurol 256(1):1-13 (Pubitemid 17005340)
52. Tikiz H, Tuncel N, Gurer F, Baycu C (1991) Mast cell degranulation in hemorrhagic shock in rats and the effects of vasoactive intestinal peptide, aprotinin and H1 and H2-receptor blockers on degranulation. Pharmacolog 43:47-52
53. Tuncel N, Tore F (1998) The effect of vasoactive intestinal peptide (VIP) inhibition of nitric oxide synthase on survival rate in rats exposed to endotoxin shock. Ann N Y Acad Sci 865:586-589 (Pubitemid 29047890)
54. Tuncel N, Basmak H, Uzuner K, Tuncel M, Altiokka G, Zaimoglu Vet al (1996) Protection of rat retina from ischemia-reperfusion injury by vasoactive intestinal peptide (VIP): the effect of VIP on lipid peroxidation and antioxidant enzyme activity of retina and choroid. Ann N Y Acad Sci 805:489-498 (Pubitemid 27058046)
55. Tuncel N, Tore F, Sahinturk V (2000) Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 21:81-89 (Pubitemid 30126046)
56. Tuncel N, Sener E, Cerit C et al (2005) Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides 26(5):827-836 (Pubitemid 40461664)
57. Tuncel N, Korkmaz OT, Tekin N, Sener E, Akyüz F, Inal M (2012) Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J Mol Neurosci 46(1):51-57
58. Villalba RM, Smith Y (2010) Striatal spine plasticity in Parkinson's disease. Front Neuroanat 10(4):133
59. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497
60. Zaja-Milatovic S, Milatovic D, Schantz AM et al (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64(3):545-547 (Pubitemid 40189880)
61. Zhang QL, Liu J, Lin PX, Webster HD (2002) Local administration of vasoactive intestinal peptide after nerve transection accelerates early myelination and growth of regenerating axons. J Peripher Nerv Syst 7:118-127 (Pubitemid 34671073)